{
  "docId": "019de076-b3a4-71cc-8183-985590ab9557",
  "docSlug": "2fc842fd1dad3dbfa44767764fb3543f",
  "documentTitle": "MaxCyte | Investor Presentation Deck | 21 slides",
  "authorId": "maxcyte",
  "authorName": "MaxCyte",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 21,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "solution",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "The slide contrasts a traditional, lengthy development process with the accelerated VLx-enabled approach.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-b3a4-71cc-8183-985590ab9557/18",
  "deckHref": "/decks/019de076-b3a4-71cc-8183-985590ab9557",
  "deckJsonHref": "/decks/019de076-b3a4-71cc-8183-985590ab9557.json",
  "deckAnchorHref": "/decks/019de076-b3a4-71cc-8183-985590ab9557#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.46,
        "w": 0.206,
        "x": 0.213,
        "y": 0.058
      },
      "kind": "image",
      "text": "VLx device image",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0478990a-e3c5-4fe4-b22e-8c446d38fee2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.445,
        "x": 0.055,
        "y": 0.535
      },
      "kind": "list",
      "text": "Transfect up to 200 billion cells in a fully closed, single-use system in less than 30 minutes; Achieve reproducible results, superior transfection efficiency, cell viability and protein expression; Bench-scale, modular equipment; Proprietary Flow Electroporation Technology; cGMP-compliant, closed, ISO-certified and CE-marked",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "528c7013-331b-47e5-abfa-07feccecc502",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.11,
        "w": 0.442,
        "x": 0.516,
        "y": 0.455
      },
      "kind": "list",
      "text": "The process begins with transiently expressing product using transfection early on in Discovery phase followed by establishing a stable cell line process (industry standard ~6+ months) in preclinical development and beyond; Stable cell line development process is lengthy, cumbersome, complex, and costly, and significantly contributes to time to IND filing",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "993ad5db-40ff-472e-8134-68b5e5f41825",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.11,
        "w": 0.442,
        "x": 0.516,
        "y": 0.735
      },
      "kind": "list",
      "text": "Expedites the production of the required amount of product (multi-gram quantify) to conduct in-vivo and in-vitro studies for IND filing in only ~4-6 weeks; This concept introduces a new “speed to product selection” strategy, enabling investment in stable cell line development only for promising/successful drug candidates",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9a395db8-9384-4236-ab60-bf8136b1e702",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.022,
        "w": 0.175,
        "x": 0.516,
        "y": 0.685
      },
      "kind": "title",
      "text": "VLx-Enabled Approach",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0dee3e0b-4a22-44b3-8380-c6e2efdd7775",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.022,
        "w": 0.155,
        "x": 0.516,
        "y": 0.398
      },
      "kind": "title",
      "text": "Traditional Approach",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9315d10a-80a7-4706-8f77-4b5684b5418c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.022,
        "w": 0.173,
        "x": 0.18,
        "y": 0.485
      },
      "kind": "title",
      "text": "VLx Platform Overview",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b444f79f-7ef4-4072-871e-ec5a6af488eb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.442,
        "x": 0.516,
        "y": 0.115
      },
      "kind": "title",
      "text": "Biotherapeutic Development: Monoclonal Antibodies, Recombinant Proteins and Vaccines",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f8a94c7b-71af-499d-98d5-d905aeb2b82b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "before-after-framing",
      "slug": null,
      "matchId": "9f64ba25-40fa-4429-bdd3-d2c01600b03f",
      "evidence": "Contrasts traditional lengthy process with accelerated VLx-enabled approach.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}